CFDE Data Portal | Search HYCC2

	Label	Description
	HYCC2 Gene (Entity type)	ENSG00000155744 - hyccin PI4KA lipid kinase complex subunit 2
	GSE114883 romidepsin T cell 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE102757 1 V 0 PANOBINOSTAT MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 3 V 5 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE148200 0 V 2 GEMCITABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE159678 4 V 2 CHLOROQUINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE114883 romidepsin T cell 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE114883 romidepsin T cell 0 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE93156 idelalisib B cell 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE255432 7 V 3 IMEGLIMIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS

HYCC2

ENSG00000155744 - hyccin PI4KA lipid kinase complex subunit 2

GSE114883 romidepsin T cell 1 v 2 human up

A Gene Set from LINCS

GSE102757 1 V 0 PANOBINOSTAT MOUSE UP

A Gene Set from LINCS

GSE135350 3 V 5 DEXAMETHASONE HUMAN UP

A Gene Set from LINCS

GSE148200 0 V 2 GEMCITABINE HUMAN UP

A Gene Set from LINCS

GSE159678 4 V 2 CHLOROQUINE HUMAN UP

A Gene Set from LINCS

GSE114883 romidepsin T cell 0 v 2 human up

A Gene Set from LINCS

GSE114883 romidepsin T cell 0 v 4 human up

A Gene Set from LINCS

GSE93156 idelalisib B cell 1 v 0 human dn

A Gene Set from LINCS

GSE255432 7 V 3 IMEGLIMIN MOUSE DN

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.